Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNXNASDAQ:MRUSNASDAQ:OPTNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$30.81+3.0%$31.00$24.10▼$62.53$2.89B0.31855,011 shs753,519 shsMRUSMerus$55.41+10.8%$42.99$33.19▼$61.28$3.83B0.94735,183 shs1.54 million shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.1226,802 shsN/ASRRKScholar Rock$29.93+3.7%$30.55$6.76▼$46.98$2.84B0.371.27 million shs271,496 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+1.39%-0.13%-9.66%-9.94%-36.17%MRUSMerus-1.56%+15.74%+10.45%+8.20%-8.86%OPTOpthea0.00%0.00%0.00%-25.87%+8.77%SRRKScholar Rock-5.28%-6.05%-8.87%-19.74%+179.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals3.7577 of 5 stars3.51.00.03.73.62.50.0MRUSMerus2.8438 of 5 stars4.62.00.00.02.61.70.0OPTOpthea0.9276 of 5 stars2.10.00.00.02.70.80.6SRRKScholar Rock4.3771 of 5 stars3.52.00.04.43.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56141.98% UpsideMRUSMerus 3.13Buy$86.0055.20% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideSRRKScholar Rock 3.00Buy$42.6742.55% UpsideCurrent Analyst Ratings BreakdownLatest OPT, CRNX, MRUS, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.003/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$760K3,795.79N/AN/A$8.07 per share3.82MRUSMerus$54.73M70.08N/AN/A$6.17 per share8.98OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09SRRKScholar Rock$33.19M85.62N/AN/A$3.12 per share9.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$214.53M-$3.82N/AN/AN/AN/A-36.12%-31.89%8/6/2025 (Estimated)MRUSMerus-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/ASRRKScholar Rock-$165.79M-$2.53N/AN/AN/AN/A-145.60%-91.83%8/14/2025 (Estimated)Latest OPT, CRNX, MRUS, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A16.3916.38MRUSMerusN/A8.328.32OPTOptheaN/A2.942.94SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%MRUSMerus96.14%OPTOpthea55.95%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals4.60%MRUSMerus4.57%OPTOpthea3.20%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.63 million87.17 millionOptionableMRUSMerus3769.21 million65.34 millionOptionableOPTOpthea8153.91 million148.98 millionNot OptionableSRRKScholar Rock14094.95 million75.64 millionOptionableOPT, CRNX, MRUS, and SRRK HeadlinesRecent News About These CompaniesScholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Polar Asset Management Partners Inc.May 29 at 5:06 AM | marketbeat.comMillennium Management LLC Sells 524,642 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 29 at 3:38 AM | marketbeat.comScholar Rock to Present at the Jefferies Global Healthcare ConferenceMay 28 at 8:00 AM | businesswire.comNuveen Asset Management LLC Buys 122,638 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 28 at 3:50 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Given Average Rating of "Buy" by BrokeragesMay 28 at 1:31 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Voloridge Investment Management LLCMay 27 at 4:46 AM | marketbeat.comBank of America Corp DE Trims Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 27 at 3:15 AM | marketbeat.comTwo Sigma Advisers LP Sells 330,600 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 25, 2025 | marketbeat.comTwo Sigma Investments LP Sells 221,365 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 25, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by ProShare Advisors LLCMay 25, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 13,394 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 23, 2025 | marketbeat.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 22, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Woodline Partners LPMay 22, 2025 | marketbeat.comSoleus Capital Management L.P. Invests $7.24 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)May 21, 2025 | marketbeat.comRafferty Asset Management LLC Sells 37,595 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 21, 2025 | marketbeat.comPolar Asset Management Partners Inc. Trims Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)May 20, 2025 | marketbeat.comDimensional Fund Advisors LP Lowers Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 20, 2025 | marketbeat.comHC Wainwright Boosts Earnings Estimates for Scholar RockMay 20, 2025 | marketbeat.comWedbush Forecasts Scholar Rock's Q2 Earnings (NASDAQ:SRRK)May 20, 2025 | americanbankingnews.comWhat is Wedbush's Estimate for Scholar Rock Q2 Earnings?May 20, 2025 | marketbeat.comDeutsche Bank AG Has $8 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Here's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock OPT, CRNX, MRUS, and SRRK Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$30.81 +0.90 (+3.01%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Merus NASDAQ:MRUS$55.41 +5.40 (+10.81%) As of 01:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 05/28/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Scholar Rock NASDAQ:SRRK$29.93 +1.07 (+3.71%) As of 01:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
